Lung Cancer TALK: A Review of Data from the IASLC 2020 World Conference on Lung Cancer - Episode 1

WCLC Updates in KRAS and Rare EGFR-Mutated NSCLC

, , ,

Experts in thoracic oncology review data presented at the IASLC 2020 World Conference on Lung Cancer (WCLC) and discuss safety and efficacy of targeted agents for patients with KRAS- or EGFR-mutated non–small cell lung cancer (NSCLC).

Now Viewing
EP. 1: WCLC Updates in KRAS and Rare EGFR-Mutated NSCLC
EP. 2: WCLC Updates on the Emergence of ADCs in NSCLC
EP. 3: WCLC Updates in Immunotherapy for NSCLC
EP. 4: WCLC Updates in Neoadjuvant Therapy for NSCLC
EP. 5: WCLC Updates in Locally Advanced NSCLC
EP. 6: WCLC Updates in Small Cell Lung Cancer

Data from the following clinical trials are discussed:

  • PS0 1.07 - CodeBreaK 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non–Small Cell Lung Cancer
  • OA04.03 - Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations
  • OA04.04 - Amivantamab in Postplatinum EGFR Exon 20 Insertion Mutant Non–Small Cell Lung Cancer